WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, April 26, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ		
☐	L43	L42 not @py>2000	4
☐	L42	L41 and l5	37
☐	L41	L40 and l19	144
☐	L40	L39 or l38	11348
☐	L39	(514/1,2,423)![CCLS]	10290
☐	L38	(424/134.1,144.1)![CCLS]	1142
☐	L37	L36 and human	1
☐	L36	5444069.pn.	1
☐	L35	L34 and l5	5
☐	L34	L33 and l25	5
☐	L33	(suthanthiran or maluccio).in.	18
☐	L32	L31 and losartan	1
☐	L31	L30 and l5	1
☐	L30	5824696.pn.	1
☐	L29	L28 and L21	14
☐	L28	L27 not @py>=2000	15
☐	L27	L26 and L5	88
☐	L26	L25.ab.	1053
☐	L25	angiotensin II	7328
☐	L24	L22 not @py>2000	80
☐	L23	L22 not @ay>2000	119
☐	L22	L21 and L20	272
☐	L21	antagoni$ or inhibit$	665630
☐	L20	L18 and L19	286
☐	L19	L16.ab.	1946
☐	L18	L5 or L6	232985
☐	L17	L16 and L5	7934
☐	L16	angiotensin$	15420
☐	L15	L6 and L13	0
☐	L14	L5 and L13	0

☐	L13	L12 or L11 or L10	31
☐	L12	(5034512 or 4894437 or 5098924 or 5055466 or 4885292 or 5075451 or 4980283 or 5066643).pn.	8
☐	L11	(5114937 or 5106835 or 5063208 or 4845079 or 4845079 or 5089471 or 5071837 or 5064965 or 5063207 or 5036054 or 5036053).pn.	10
☐	L10	(4168267 or 4337201 or 5256687 or 4316906 or 5589499 or 4452740 or 4432970 or 5116835 or 5095119 or 5104869).pn.	13
☐	L9	L4 and L6	1
☐	L8	L5 and L4	1
☐	L7	L5 an dl4	0
☐	L6	angiogen$ or neovascu$ or prolifer$	119958
☐	L5	cancer$ or tumor$ or neoplas$	187735
☐	L4	L3 or L2 or L1	21
☐	L3	4508729.pn.	1
☐	L2	(4316906 or 4374829 or 4344949 or 450879 or 4587256 or 5045553 or 4410520 or 4512924).pn.	9
☐	L1	(5608075 or 5087643 or 6004989 or 6001881 or 598884 or 5234581 or 5889020 or 4473575 or 4105776).pn.	11

END OF SEARCH HISTORY

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  DEC 23   New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                   USPAT2
 NEWS  4  JAN 13   IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS  5  JAN 13   New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                   INPADOC
 NEWS  6  JAN 17   Pre-1988 INPI data added to MARPAT
 NEWS  7  JAN 17   IPC 8 in the WPI family of databases including WPIFV
 NEWS  8  JAN 30   Saved answer limit increased
 NEWS  9  FEB 21   STN AnaVist, Version 1.1, lets you share your STN AnaVist
                   visualization results
 NEWS 10  FEB 22   The IPC thesaurus added to additional patent databases on STN
 NEWS 11  FEB 22   Updates in EPFULL; IPC 8 enhancements added
 NEWS 12  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS 13  FEB 28   MEDLINE/LMEDLINE reload improves functionality
 NEWS 14  FEB 28   TOXCENTER reloaded with enhancements
 NEWS 15  FEB 28   REGISTRY/ZREGISTRY enhanced with more experimental spectral
                   property data
 NEWS 16  MAR 01   INSPEC reloaded and enhanced
 NEWS 17  MAR 03   Updates in PATDPA; addition of IPC 8 data without attributes
 NEWS 18  MAR 08   X.25 communication option no longer available after June 2006
 NEWS 19  MAR 22   EMBASE is now updated on a daily basis
 NEWS 20  APR 03   New IPC 8 fields and IPC thesaurus added to PATDPAFULL
 NEWS 21  APR 03   Bibliographic data updates resume; new IPC 8 fields and IPC
                   thesaurus added in PCTFULL
 NEWS 22  APR 04   STN AnaVist $500 visualization usage credit offered
 NEWS 23  APR 12   LINSPEC, learning database for INSPEC, reloaded and enhanced
 NEWS 24  APR 12   Improved structure highlighting in FQHIT and QHIT display
                   in MARPAT
 NEWS 25  APR 12   Derwent World Patents Index to be reloaded and enhanced during
                   second quarter; strategies may be affected

 NEWS EXPRESS  FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
```

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 APR 2006 HIGHEST RN 881879-55-6
DICTIONARY FILE UPDATES: 25 APR 2006 HIGHEST RN 881879-55-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> E "LOSARTAN"/CN 25
E1 1 LOSAN/CN
E2 1 LOSANTIN/CN
E3 1 --> LOSARTAN/CN
E4 1 LOSARTAN MONOPOTASSIUM SALT/CN
E5 1 LOSARTAN P-TOLUENESULFONATE/CN
E6 1 LOSARTAN POTASSIUM/CN
E7 1 LOSARTAN-HYDROCHLOROTHIAZIDE MIXT./CN
E8 1 LOSBANINE/CN
E9 1 LOSE-URONATE KETOL-ISOMERASE (YERSINIA PESTIS STRAIN CO92 GENE KDUI)/CN
E10 1 LOSEC/CN

```
E11          1     LOSEC SODIUM/CN
E12          1     LOSEYITE/CN
E13          1     LOSFERRON/CN
E14          1     LOSIGAMONE/CN
E15          1     LOSIL 1000-50/CN
E16          1     LOSIL 1000-65/CN
E17          1     LOSIL 800-50/CN
E18          1     LOSIL 800-65/CN
E19          1     LOSINDOLE/CN
E20          1     LOSK/CN
E21          1     LOSMIPROFEN/CN
E22          1     LOSO PREP/CN
E23          1     LOSOL BLUE/CN
E24          1     LOSOXANTRONE/CN
E25          1     LOSOXANTRONE HYDROCHLORIDE/CN

=> S E3
L1           1 LOSARTAN/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   114798-26-4  REGISTRY
CN   1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-
     biphenyl]-4-yl]methyl]- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   DUP 89
CN   Lortaan
CN   Losartan
FS   3D CONCORD
MF   C22 H23 Cl N6 O
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN,
       CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS,
       IMSRESEARCH, MEDLINE, MRCK*, PATDPASPC, PROMT, PROUSDDR, RTECS*,
       SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   WHO
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PROC
       (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL (Biological
       study); PREP (Preparation); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
       (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  BIOL (Biological
       study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2404 REFERENCES IN FILE CA (1907 TO DATE)
31 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2414 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> E "ENALAPRIL"/CN 25
E1            1     ENALADIL/CN
E2            1     ENALAPRAT/CN
E3            1 --> ENALAPRIL/CN
E4            1     ENALAPRIL ACETATE/CN
E5            1     ENALAPRIL ACID/CN
E6            1     ENALAPRIL BENZYL ESTER/CN
E7            1     ENALAPRIL CALCIUM DIHYDRATE/CN
E8            1     ENALAPRIL DIACID/CN
E9            1     ENALAPRIL DIKETOPIPERAZINE/CN
E10           1     ENALAPRIL DKP/CN
E11           1     ENALAPRIL HYDROCHLORIDE/CN
E12           1     ENALAPRIL MALEATE/CN
E13           1     ENALAPRIL MALEATE-HYDROCHLOROTHIAZIDE MIXT./CN
E14           1     ENALAPRIL SODIUM/CN
E15           1     ENALAPRIL TERT-BUTYL ESTER/CN
E16           1     ENALAPRIL-KETANSERIN MIXT./CN
E17           1     ENALAPRILAT/CN
E18           1     ENALAPRILAT SRS/CN
E19           1     ENALAPRILAT-KETANSERIN MIXT./CN
E20           1     ENALAPRILATE/CN
E21           1     ENALAPRILIC ACID/CN
E22           1     ENALIN A/CN
E23           1     ENALIN B/CN
E24           1     ENALITE/CN
E25           1     ENALKIREN/CN

=> S E3
L2            1 ENALAPRIL/CN

=> DIS L2 1 RN

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   75847-73-3  REGISTRY


=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                12.51      12.72

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

FILE COVERS 1907 - 26 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 25 Apr 2006 (20060425/ED)


```
=> s l1 or l2
          2414 L1
          2695 L2
L3        4684 L1 OR L2

=> s cancer? or tumor? or neoplas?
        290705 CANCER?
        425403 TUMOR?
        446494 NEOPLAS?
L4      704495 CANCER? OR TUMOR? OR NEOPLAS?

=> s l4 and l3
L5         146 L4 AND L3

=> s l3 (L) l4
L6          22 L3 (L) L4

=> s l6 not py>2000
       5711376 PY>2000
L7           3 L6 NOT PY>2000

=> d ibib 1-3

L7   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        1999:794097  CAPLUS
DOCUMENT NUMBER:         132:18639
TITLE:                   Do ACE-inhibitors suppress tumor necrosis
                         factor-α production in advanced chronic renal
                         failure?
AUTHOR(S):               Stenvinkel, P.; Andersson, P.; Wang, T.; Lindholm, B.;
                         Bergstrom, J.; Palmblad, J.; Heimburger, O.;
                         Cederholm, T.
CORPORATE SOURCE:        Departments of Clinical Science, Divisions of Renal
                         Medicine and Baxter Novum, Stockholm, Swed.
SOURCE:                  Journal of Internal Medicine (1999), 246(5), 503-507
                         CODEN: JINMEO; ISSN: 0954-6820
PUBLISHER:               Blackwell Science Ltd.
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         22    THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:688629 CAPLUS
DOCUMENT NUMBER: 132:175414
TITLE: Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry
AUTHOR(S): Gallez, Bernard; Jordan, Benedicte F.; Baudelet, Christine; Misson, Pierre-Damien
CORPORATE SOURCE: Laboratory of Medicinal Chemistry and Radiopharmacy, Universite Catholique de Louvain, Brussels, Belg.
SOURCE: Magnetic Resonance in Medicine (1999), 42(4), 627-630
CODEN: MRMEEN; ISSN: 0740-3194
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:845231 CAPLUS
DOCUMENT NUMBER: 123:275949
TITLE: Angiotensin-converting-enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells
AUTHOR(S): Schindler, Ralf; Dinarello, Charles A.; Koch, Karl-M.
CORPORATE SOURCE: Department of Nephrology, Medical School Hannover, Berlin, D-14050, Germany
SOURCE: Cytokine (1995), 7(6), 526-33
CODEN: CYTIE9; ISSN: 1043-4666
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d ibibi abs 2
'IBIBI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels

```
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):ibib

L7   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1999:688629  CAPLUS
DOCUMENT NUMBER:          132:175414
TITLE:                    Pharmacological modifications of the partial pressure
                          of oxygen in murine tumors: evaluation using in vivo
                          EPR oximetry
AUTHOR(S):                Gallez, Bernard; Jordan, Benedicte F.; Baudelet,
                          Christine; Misson, Pierre-Damien
CORPORATE SOURCE:         Laboratory of Medicinal Chemistry and Radiopharmacy,
                          Universite Catholique de Louvain, Brussels, Belg.
SOURCE:                   Magnetic Resonance in Medicine (1999), 42(4), 627-630
                          CODEN: MRMEEN; ISSN: 0740-3194
PUBLISHER:                Wiley-Liss, Inc.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
REFERENCE COUNT:          12    THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d ibib abs 2

L7   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1999:688629  CAPLUS
DOCUMENT NUMBER:          132:175414
TITLE:                    Pharmacological modifications of the partial pressure
                          of oxygen in murine tumors: evaluation using in vivo
                          EPR oximetry
```

AUTHOR(S): Gallez, Bernard; Jordan, Benedicte F.; Baudelet, Christine; Misson, Pierre-Damien
CORPORATE SOURCE: Laboratory of Medicinal Chemistry and Radiopharmacy, Universite Catholique de Louvain, Brussels, Belg.
SOURCE: Magnetic Resonance in Medicine (1999), 42(4), 627-630
CODEN: MRMEEN; ISSN: 0740-3194
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB EPR oximetry using an implantable paramagnetic probe was used to quantify the partial pressure of O (pO2) in tissues in a transplantable mouse tumor model after administration of 34 different vasodilators belonging to one of the following classes: angiotensin-converting enzyme inhibitors, Ca2+ antagonists, α-antagonists, K+ channel openers, β-blockers, NO donors, and peripheral vasoactive agents. Twenty-four compds. were efficient in significantly increasing the local pO2 in a majority of tumors. The increase of local pO2 by the pharmacol. treatments was lower than that achieved by using O or carbogen breathing. This technique offers a tool for rapidly and accurately measuring treatment-induced modifications of pO2 in tumors.
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s prolif? or angiogen? or neovascular?
        240616 PROLIF?
         35334 ANGIOGEN?
          7034 NEOVASCULAR?
L8      266785 PROLIF? OR ANGIOGEN? OR NEOVASCULAR?

=> d his

     (FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

     FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006
                E "LOSARTAN"/CN 25
L1            1 S E3
                E "ENALAPRIL"/CN 25
L2            1 S E3

     FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006
L3         4684 S L1 OR L2
L4       704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5          146 S L4 AND L3
L6           22 S L3 (L) L4
L7            3 S L6 NOT PY>2000
L8       266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?

=> s l8 and l3
L9          220 L8 AND L3

=> s l8 (l) l3
L10          46 L8 (L) L3

=> s l10 not py>2000
       5711376 PY>2000
L11          18 L10 NOT PY>2000

=> d ibib 1-6

L11 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:23055 CAPLUS
DOCUMENT NUMBER: 134:161364
```

TITLE: Retinal neovascularization is prevented by blockade of the renin-angiotensin system
AUTHOR(S): Moravski, Christina J.; Kelly, Darren J.; Cooper, Mark E.; Gilbert, Richard E.; Bertram, John F.; Shahinfar, Shahnaz; Skinner, Sandford L.; Wilkinson-Berka, Jennifer L.
CORPORATE SOURCE: Department of Physiology, The University of Melbourne, Parkville, 3010, Australia
SOURCE: Hypertension (2000), 36(6), 1099-1104
CODEN: HPRTDN; ISSN: 0194-911X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:871260 CAPLUS
DOCUMENT NUMBER: 135:322
TITLE: The effect of losartan on intimal thickening in rats after vascular balloon injury
AUTHOR(S): Li, Yonghong; Dong, Guoxiong; Guo, Minglei
CORPORATE SOURCE: Department of Emergency, The Affiliated Hospital of Qingdao University Medical College, Tsingtao, 266003, Peop. Rep. China
SOURCE: Qingdao Daxue Yixueyuan Xuebao (2000), 36(4), 271-273
CODEN: QDYXAE
PUBLISHER: Qingdao Daxue Yixueyuan Xuebao Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

L11 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:808012 CAPLUS
DOCUMENT NUMBER: 134:290166
TITLE: Antagonistic effect of monocyte chemotactic protein-1 monoclonal antibody and losartan on proliferation and migration of Ang-II-mediated VSMCs in vitro
AUTHOR(S): He, Zuo-yun; Li, Ai-min
CORPORATE SOURCE: Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chungking, 400037, Peop. Rep. China
SOURCE: Di-San Junyi Daxue Xuebao (2000), 22(9), 815-818
CODEN: DYXUE8; ISSN: 1000-5404
PUBLISHER: Di-San Junyi Daxue
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

L11 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:413731 CAPLUS
DOCUMENT NUMBER: 133:246971
TITLE: The stimulating effects of neuropeptide Y on cultured arterial smooth muscle cell proliferation and losartan treatment
AUTHOR(S): Huang, Shao-Hua; Liu, Jian-Kang; Chen, Min-Sheng
CORPORATE SOURCE: First Affiliated Hospital, Guangzhou Medical College, Canton, 510182, Peop. Rep. China
SOURCE: Zhongguo Bingli Shengli Zazhi (2000), 16(3), 211-213
CODEN: ZBSZEB; ISSN: 1000-4718
PUBLISHER: Jinan Daxue
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

L11 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:307168 CAPLUS
DOCUMENT NUMBER: 133:187796
TITLE: Enalapril inhibits growth and proliferation of various tissues in rat normotensive four-sixths kidney ablation nephropathy
AUTHOR(S): Gajdos, Martin; Krivosikova, Zora; Sebekova, Katarina; Lajdova, Ingrid; Spustova, Viera; Dzurik, Rastislav
CORPORATE SOURCE: Institute of Preventive and Clinical Medicine, Bratislava, 833 01, Slovakia
SOURCE: Kidney & Blood Pressure Research (2000), 23(2), 106-112
CODEN: KBPRFC; ISSN: 1420-4096
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:52976 CAPLUS
DOCUMENT NUMBER: 132:329674
TITLE: Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat
AUTHOR(S): Krivosikova, Z.; Sebekova, K.; Spustova, V.; Lajdova, I.; Dzurik, R.
CORPORATE SOURCE: Institute of Preventive and Clinical Medicine, Bratislava, Slovakia
SOURCE: Physiological Research (Prague) (1999), 48(6), 429-435
CODEN: PHRSEJ; ISSN: 0862-8408
PUBLISHER: Institute of Physiology, Academy of Sciences of the Czech Republic
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib 7-12

L11 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:14644 CAPLUS
DOCUMENT NUMBER: 132:288508
TITLE: Smooth muscle cell proliferation in the ductus arteriosus and the descending aorta, and effects of enalapril on SMC proliferation in perinatal rats
AUTHOR(S): Takizawa, Tatsuya; Kawahata, Mariko; Ikeda, Yoshinori; Yamamoto, Masako; Arishima, Kazuyoshi; Muto, Makoto; Masaoka, Toshio
CORPORATE SOURCE: Departments of Developmental and Reproductive Biotechnology, Azabu University School of Veterinary Medicine, Sagamihara, 229-8501, Japan
SOURCE: Journal of Veterinary Medical Science (1999), 61(11), 1215-1218
CODEN: JVMSEQ; ISSN: 0916-7250
PUBLISHER: Japanese Society of Veterinary Science
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:649604 CAPLUS

DOCUMENT NUMBER: 132:178991
TITLE: Effect of angiotensin II receptor antagonist on proliferation of glomerular mesangial cells from spontaneously hypertensive rats
AUTHOR(S): Chen, Shaoxing; Guo, Jizhen; Qiang, Weiguo; Du, Jian; Liu, Xiaoping; Zhu, Dingliang
CORPORATE SOURCE: Department of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Second Medical University, Shanghai, 200025, Peop. Rep. China
SOURCE: Shanghai Dier Yike Daxue Xuebao (1999), 19(4), 292-294
CODEN: SDDXE3; ISSN: 0258-5898
PUBLISHER: Shanghai Dier Yike Daxue Xuebao Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

L11 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:360095 CAPLUS
DOCUMENT NUMBER: 131:179549
TITLE: Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model
AUTHOR(S): Wilson, David P.; Saward, Laura; Zahradka, Peter; Kee Cheung, Po
CORPORATE SOURCE: Department of Physiology, University of Manitoba, MB, Can.
SOURCE: Cardiovascular Research (1999), 42(3), 761-772
CODEN: CVREAU; ISSN: 0008-6363
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:306644 CAPLUS
DOCUMENT NUMBER: 131:68521
TITLE: Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury
AUTHOR(S): Nozawa, Yoshihisa; Matsuura, Naosuke; Miyake, Hidekazu; Yamada, Shizuo; Kimura, Ryohei
CORPORATE SOURCE: Pharmacology Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, 771-0194, Japan
SOURCE: Life Sciences (1999), 64(22), 2061-2070
CODEN: LIFSAK; ISSN: 0024-3205
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:284031 CAPLUS
DOCUMENT NUMBER: 129:36278
TITLE: Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats
AUTHOR(S): Taylor, Kenneth; Patten, Richard D.; Smith, John J.; Aronovitz, Mark J.; Wight, Joseph; Salomon, Robert N.; Konstam, Marvin A.
CORPORATE SOURCE: Division of Cardiology, Department of Medicine, New

England Medical Center, Tufts University School of Medicine, Boston, MA, 02111, USA
SOURCE: Journal of Cardiovascular Pharmacology (1998), 31(5), 654-660
CODEN: JCPCDT; ISSN: 0160-2446
PUBLISHER: Lippincott-Raven Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:108045 CAPLUS
DOCUMENT NUMBER: 126:195036
TITLE: In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation
AUTHOR(S): Virone-Oddos, A.; Desangle, V.; Provost, D.; Cazes, M.; Caussade, F.; Cloarec, A.
CORPORATE SOURCE: Lab. UPSA, Rueil-Malmaison, 92506, Fr.
SOURCE: British Journal of Pharmacology (1997), 120(3), 488-494
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Stockton
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006
E "LOSARTAN"/CN 25
L1 1 S E3
E "ENALAPRIL"/CN 25
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006
L3 4684 S L1 OR L2
L4 704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5 146 S L4 AND L3
L6 22 S L3 (L) L4
L7 3 S L6 NOT PY>2000
L8 266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9 220 S L8 AND L3
L10 46 S L8 (L) L3
L11 18 S L10 NOT PY>2000

=> s l10 and l4
L12 7 L10 AND L4

=> d ibib 1-7

L12 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:182557 CAPLUS
DOCUMENT NUMBER: 144:267234
TITLE: Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells
AUTHOR(S): Liu, Wen-Bin; Wang, Xing-Peng; Wu, Kai; Zhang, Ru-Ling
CORPORATE SOURCE: Shanghai No. 1 People's Hospital, Shanghai Jiaotong

University, Shanghai, 200080, Peop. Rep. China
SOURCE: World Journal of Gastroenterology (2005), 11(41), 6489-6494
CODEN: WJGAF2; ISSN: 1007-9327
PUBLISHER: World Journal of Gastroenterology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:577447 CAPLUS
DOCUMENT NUMBER: 143:379379
TITLE: Effects of Combined Endothelin and Angiotensin II Antagonism on Growth Factor-Induced Proliferation of Vascular Smooth Muscle Cells Isolated from Uremic Rats
AUTHOR(S): Wolf, Sabine; Sauter, Gabriele; Risler, Teut; Brehm, Bernhard
CORPORATE SOURCE: Medical Clinic IV, Department of Hypertension and Renal Failure and Endocrinology, University of Tuebingen, Tuebingen, Germany
SOURCE: Renal Failure (2005), 27(4), 465-474
CODEN: REFAE8; ISSN: 0886-022X
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:291659 CAPLUS
DOCUMENT NUMBER: 143:323408
TITLE: Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma
AUTHOR(S): Arrieta, O.; Guevara, P.; Escobar, E.; Garcia-Navarrete, R.; Pineda, B.; Sotelo, J.
CORPORATE SOURCE: Neuroimmunology Unit of the National Institute of Neurology and Neurosurgery of Mexico, Mexico City, 14269, Mex.
SOURCE: British Journal of Cancer (2005), 92(7), 1247-1252
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:88914 CAPLUS
DOCUMENT NUMBER: 142:403819
TITLE: Influence of growth factors on the proliferation of vascular smooth muscle cells isolated from subtotally nephrectomized rats after endothelin or angiotensin II antagonism
AUTHOR(S): Wolf, Sabine C.; Sauter, Gabriele; Rodemann, Hans-Peter; Risler, Teut; Brehm, Bernhard R.
CORPORATE SOURCE: Medical Clinic III, Department of Cardiology, Nephrology, Hypertension and Renal Failure, Eberhard-Karls-University, Tuebingen, D-72076, Germany
SOURCE: Nephrology, Dialysis, Transplantation (2005), 20(2), 312-318
CODEN: NDTREA; ISSN: 0931-0509

PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:777526 CAPLUS
DOCUMENT NUMBER: 139:286322
TITLE: PAR receptor-mediated antiangiogenic activity of thrombin and use of PAR receptor agonists for the treatment of **cancer** and other angiogenesis-associated diseases
INVENTOR(S): Sukhatme, Vikas P.; Merchan, Jaime; Chan, Barden
PATENT ASSIGNEE(S): Beth Israel Deaconess Medical Center, USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003079978	A2	20031002	WO 2003-US8121		20030314
WO 2003079978	A3	20040226			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003218213	A1	20031008	AU 2003-218213		20030314
US 2005232925	A1	20051020	US 2005-508317		20050616
PRIORITY APPLN. INFO.:			US 2002-365165P	P	20020318
			WO 2003-US8121	W	20030314

L12 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:272945 CAPLUS
DOCUMENT NUMBER: 139:301459
TITLE: The effect of commonly used drugs on angiogenesis
AUTHOR(S): Sartippour, Maryam R.; De Leon, Ernesto; Rubio, Rosalio; Brooks, Mai N.
CORPORATE SOURCE: Department of Surgery, Division of Oncology, University of California, Los Angeles, CA, 90095, USA
SOURCE: Anticancer Research (2003), 23(1A), 231-234
CODEN: ANTRD4; ISSN: 0250-7005
PUBLISHER: International Institute of Anticancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:14362 CAPLUS
DOCUMENT NUMBER: 136:379590
TITLE: AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma
AUTHOR(S): Rivera, E.; Arrieta, O.; Guevara, P.; Duarte-Rojo, A.;

```
                          Sotelo, J.
CORPORATE SOURCE:         Neuroimmunology Unit, National Institute of Neurology
                          and Neurosurgery of Mexico, Mexico, 14269, Mex.
SOURCE:                   British Journal of Cancer (2001), 85(9), 1396-1399
                          CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER:                Harcourt Publishers Ltd.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
REFERENCE COUNT:          34    THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s losartan or enalapril
          4562 LOSARTAN
             1 LOSARTANS
          4562 LOSARTAN
                 (LOSARTAN OR LOSARTANS)
          3733 ENALAPRIL
L13       7727 LOSARTAN OR ENALAPRIL

=> d his

     (FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

     FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006
                E "LOSARTAN"/CN 25
L1            1 S E3
                E "ENALAPRIL"/CN 25
L2            1 S E3

     FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006
L3         4684 S L1 OR L2
L4       704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5          146 S L4 AND L3
L6           22 S L3 (L) L4
L7            3 S L6 NOT PY>2000
L8       266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9          220 S L8 AND L3
L10          46 S L8 (L) L3
L11          18 S L10 NOT PY>2000
L12           7 S L10 AND L4
L13        7727 S LOSARTAN OR ENALAPRIL

=> s l13 (l) l4
L14          92 L13 (L) L4

=> s l14 not py>2000
       5711376 PY>2000
L15          28 L14 NOT PY>2000

=> s l14 not py>1999
       6603140 PY>1999
L16          23 L14 NOT PY>1999

=> s l16 and l8
L17           4 L16 AND L8

=> d ibib 1-4

L17  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1998:204801  CAPLUS
DOCUMENT NUMBER:          128:304377
TITLE:                    Angiotensin II-induced Ca2+ mobilization and prolactin
```

release in normal and hyperplastic pituitary cells
AUTHOR(S): Diaz-Torga, Graciela; Gonzelez Iglesias, Arturo; Achaval-Zaia, Rita; Libertun, Carlos; Becu-Villalobos, Damasia
CORPORATE SOURCE: Inst. Biologia Medicina Experimental, Consejo Investigaciones Cientificas Tecnicas, Buenos Aires, 1428, Argent.
SOURCE: American Journal of Physiology (1998), 274(3, Pt. 1), E534-E540
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:256278 CAPLUS
DOCUMENT NUMBER: 126:329068
TITLE: Sequential development of angiotensin receptors and angiotensin I converting enzyme during **angiogenesis** in the rat subcutaneous sponge granuloma
AUTHOR(S): Walsh, David A.; Hu, De-En; Wharton, John; Catravas, John D.; Blake, David R.; Fan, Tai-Ping D.
CORPORATE SOURCE: Inflammation Group, London Hospital Medical College, London, E1 2AD, UK
SOURCE: British Journal of Pharmacology (1997), 120(7), 1302-1311
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Stockton
DOCUMENT TYPE: Journal
LANGUAGE: English

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:939339 CAPLUS
DOCUMENT NUMBER: 124:52845
TITLE: Is estrogen-induced pituitary hyperplasia and hyperprolactinemia mediated by angiotensin II?
AUTHOR(S): Pawlikowski, M.; Mucha, S.; Kunert-Radek, J.; Sepien, H.; Pisarek, H.; Stawowy, A.
CORPORATE SOURCE: Institute Endocrinology, Medical University Lodz, Lodz, Pol.
SOURCE: Advances in Experimental Medicine and Biology (1995), 377(Tissue Renin-Angiotensin Systems), 371-8
CODEN: AEMBAP; ISSN: 0065-2598
PUBLISHER: Plenum
DOCUMENT TYPE: Journal
LANGUAGE: English

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:845231 CAPLUS
DOCUMENT NUMBER: 123:275949
TITLE: Angiotensin-converting-enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells
AUTHOR(S): Schindler, Ralf; Dinarello, Charles A.; Koch, Karl-M.
CORPORATE SOURCE: Department of Nephrology, Medical School Hannover, Berlin, D-14050, Germany
SOURCE: Cytokine (1995), 7(6), 526-33
CODEN: CYTIE9; ISSN: 1043-4666
PUBLISHER: Academic
DOCUMENT TYPE: Journal

LANGUAGE: English

=> d kwic 1-2

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . on prolactin release, intracellular calcium ([Ca2+]i) mobilization, and [3H]thymidine uptake in cells from normal rat pituitaries and from estrogen-induced pituitary **tumors**. ANG II (10-7 to 10-9 M) increased prolactin release significantly in control and not in **tumoral** cells. In control cells, ANG II (10-6 to 10-9 M) produced an immediate spike of [Ca2+]i followed by a plateau.. . . significantly between 10-10 and 10-8 M ANG II, whereas the onset of the spike was retarded with decreasing concns. In **tumoral** cells, ANG II did not produce a spike phase even at 10-6 M. ANG II-induced prolactin release and calcium mobilization were blocked by **losartan** (AT1 receptor antagonist) and not by PD-123319 (AT2 antagonist). Finally, [3H]thymidine uptake was not modified by ANG II (10-7 to. . . estrogenic treatment alters in vitro pituitary response to ANG II. Alterations might function to limit excessive prolactin secretion of hypersecreting **tumors**. Besides, ANG II does not modify DNA synthesis in vitro of cells from normal or **tumor** -derived hypophyses.
IT Cell **proliferation**
Pituitary gland
(angiotensin II-induced Ca2+ mobilization and prolactin release in normal and hyperplastic pituitary cells)

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Sequential development of angiotensin receptors and angiotensin I converting enzyme during **angiogenesis** in the rat subcutaneous sponge granuloma
AB The vasoconstrictor peptide angiotensin II (AII) can stimulate **angiogenesis**, an important process in wound healing, **tumor** growth and chronic inflammation. To elucidate mechanisms underlying AII-enhanced **angiogenesis**, we have studied a s.c. sponge granuloma model in the rat by use of 133Xe clearance, morphometry and quant. in. . . directly into the sponge, AII (1 nmol day-1) increased 133Xe clearance from, and fibrovascular growth in sponge granulomas, indicating enhanced **angiogenesis** 6 to 12 days after implantation. This AII-enhanced **angiogenesis** was inhibited by daily doses (100 nmol/sponge) of the specific but subtype non-selective AII receptor antagonist (Sar1, Ile8)AII, and by the selective non-peptide AT1 receptor antagonists **losartan** and DuP 532. In contrast, AII-enhanced **neovascularization** was not inhibited by the AT2 receptor antagonist PD123319, nor was it mimicked by the AT2 receptor agonist CGP42112A (each. . . (ACE) inhibitors captopril (up to 100 μg/sponge day-1) and lisinopril (40 μg/sponge day-1), or AII receptor antagonists did not affect **angiogenesis** in the absence of exogenous AII. [125I]-(Sar1, Ile8)AII binding sites with characteristics of AT1 receptors were localized to microvessels and. . . days after sponge implantation. [125I]-351A bound less densely to sponge stroma than to skin. We propose that AII can stimulate **angiogenesis**, acting via AT1 receptors within the sponge granuloma. AT1 and AT2 receptors and ACE develop sequentially during microvascular maturation, and the role of the endogenous angiotensin system in **angiogenesis** will depend on the balanced local expression of its various components. Pharmacol. modulation of this balance may provide novel therapeutic approaches in **angiogenesis** -dependent diseases.
ST angiotensin receptor ACE **angiogenesis**
IT Angiotensin receptors
RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(AT1; sequential development of angiotensin receptors and ACE during **angiogenesis** in rat s.c. sponge granuloma)

IT Angiotensin receptors
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(AT2; sequential development of angiotensin receptors and ACE during **angiogenesis** in rat s.c. sponge granuloma)

IT Disease, animal
(**angiogenesis**-dependent; sequential development of angiotensin receptors and ACE during **angiogenesis** in rat s.c. sponge granuloma in relation to treatment of **angiogenesis**-dependent diseases)

IT **Angiogenesis**
(**neovascularization**; sequential development of angiotensin receptors and ACE during **angiogenesis** in rat s.c. sponge granuloma)

IT Granuloma
(sequential development of angiotensin receptors and ACE during **angiogenesis** in rat s.c. sponge granuloma)

IT **Angiogenesis**
(sequential development of angiotensin receptors and ACE during **angiogenesis** in rat s.c. sponge granuloma in relation to treatment of **angiogenesis**-dependent diseases)

IT 9015-82-1, Angiotensin I converting enzyme 11128-99-7, Angiotensin II
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(sequential development of angiotensin receptors and ACE during **angiogenesis** in rat s.c. sponge granuloma)

=> d kwic 3

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . role of angiotensin II (AII) in estrogen action on the rat anterior pituitary gland. AII is able to enhance the **proliferation** of cells isolated from estrogen-induced pituitary **tumors**, as well as cells isolated from human pituitary adenomas. Angiotensin-converting enzyme inhibitors **enalapril** and enalprilate decreased the cell **proliferation** indexes of DES-induced pituitary **tumors**. AII receptor blockers diminished the d. of prolactin-immunoreactive cells in DES-induced pituitary **tumors**.

=> d 3 abs

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AB A study was done to investigate the role of angiotensin II (AII) in estrogen action on the rat anterior pituitary gland. AII is able to enhance the **proliferation** of cells isolated from estrogen-induced pituitary **tumors**, as well as cells isolated from human pituitary adenomas. Angiotensin-converting enzyme inhibitors **enalapril** and enalprilate decreased the cell **proliferation** indexes of DES-induced pituitary **tumors**. AII receptor blockers diminished the d. of prolactin-immunoreactive cells in DES-induced pituitary **tumors**.

=> d his

```
     (FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

     FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006
                E "LOSARTAN"/CN 25
L1            1 S E3
                E "ENALAPRIL"/CN 25
L2            1 S E3

     FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006
L3         4684 S L1 OR L2
L4       704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5          146 S L4 AND L3
L6           22 S L3 (L) L4
L7            3 S L6 NOT PY>2000
L8       266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9          220 S L8 AND L3
L10          46 S L8 (L) L3
L11          18 S L10 NOT PY>2000
L12           7 S L10 AND L4
L13        7727 S LOSARTAN OR ENALAPRIL
L14          92 S L13 (L) L4
L15          28 S L14 NOT PY>2000
L16          23 S L14 NOT PY>1999
L17           4 S L16 AND L8

=> file pctfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    73.64      86.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.75      -3.75

FILE 'PCTFULL' ENTERED AT 10:25:28 ON 26 APR 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:         25 APR 2006      <20060425/UP>
MOST RECENT UPDATE WEEK:       200616        <200616/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
    SEE
    http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
    (last updated April 10, 2006) <<<

=> s losartan or enalapril
          1362 LOSARTAN
             1 LOSARTANS
          1362 LOSARTAN
                 (LOSARTAN OR LOSARTANS)
          2445 ENALAPRIL
             3 ENALAPRILS
          2445 ENALAPRIL
                 (ENALAPRIL OR ENALAPRILS)
L18       2831 LOSARTAN OR ENALAPRIL

=> s cancer? or tumor? or neoplas?
         77585 CANCER?
```

```
         64916 TUMOR?
         22498 NEOPLAS?
L19      96710 CANCER? OR TUMOR? OR NEOPLAS?

=> s l18 and l19
L20       1575 L18 AND L19

=> s l18/clm
           284 LOSARTAN/CLM
           458 ENALAPRIL/CLM
L21        571 (LOSARTAN/CLM OR ENALAPRIL/CLM)

=> s l19/clm
         22195 CANCER?/CLM
         15078 TUMOR?/CLM
          3646 NEOPLAS?/CLM
L22      31673 (CANCER?/CLM OR TUMOR?/CLM OR NEOPLAS?/CLM)

=> s l21 and l22
L23        141 L21 AND L22

=> s l23 not py>2000
        592560 PY>2000
L24         15 L23 NOT PY>2000

=> s l24 not py>1999
        672418 PY>1999
L25         12 L24 NOT PY>1999

=> d ibib 1-6

L25    ANSWER 1 OF 12    PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        1999043663 PCTFULL  ED 20020515
TITLE (ENGLISH):         N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA
                         DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR
                         THE TREATMENT OF ISCHEMIA
TITLE (FRENCH):          DERIVES DE LA N-[(A CYCLE DI OU TRIAZA DIINSATURE
                         SUBSTITUE) CARBONYLE] GUANIDINE UTILISES POUR LE
                         TRAITEMENT DE L'ISCHEMIE
INVENTOR(S):             HAMANAKA, Ernest, S.;
                         GUZMAN-PEREZ, Angel;
                         RUGGERI, Roger, B.;
                         WESTER, Ronald, T.;
                         MULARSKI, Christian, J.
PATENT ASSIGNEE(S):      PFIZER PRODUCTS INC.;
                         HAMANAKA, Ernest, S.;
                         GUZMAN-PEREZ, Angel;
                         RUGGERI, Roger, B.;
                         WESTER, Ronald, T.;
                         MULARSKI, Christian, J.
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER              KIND     DATE
                         --------------------------------
                         WO 9943663            A1 19990902
DESIGNATED STATES
       W:                AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
                         ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
                         KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
                         RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
                         ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ
                         TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT
```

SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1999-IB206 A 19990205
PRIORITY INFO.: US 1998-60/076,362 19980227

L25 ANSWER 2 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999030690 PCTFULL ED 20020515
TITLE (ENGLISH): ORAL DELIVERY FORMULATION
TITLE (FRENCH): FORMULATION D'ADMINISTRATION PAR VOIE ORALE
INVENTOR(S): COMPTON, Bruce, Jon;
SOLARI, Nancy, E.;
FLANAGAN, Margaret, A.
PATENT ASSIGNEE(S): AXIA THERAPEUTICS, INC.;
COMPTON, Bruce, Jon;
SOLARI, Nancy, E.;
FLANAGAN, Margaret, A.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9930690	A1	19990624

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-US26627 A 19981215
PRIORITY INFO.: US 1997-60/069,501 19971215
US 1998-60/073,867 19980204
US 1998-09/055,163 19980404
US 1998-09/055,560 19980406

L25 ANSWER 3 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999018956 PCTFULL ED 20020515
TITLE (ENGLISH): 12(S)-HETE RECEPTOR BLOCKERS
TITLE (FRENCH): INHIBITEURS DU RECEPTEUR DE 12(S)-HETE
INVENTOR(S): NATARAJAN, Rama, Devi;
NADLER, Jerry, L.
PATENT ASSIGNEE(S): CITY OF HOPE
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9918956	A1	19990422

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-US21570 A 19981014
PRIORITY INFO.: US 1997-60/062,335 19971015

L25 ANSWER 4 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999008596 PCTFULL ED 20020515
TITLE (ENGLISH): MEASUREMENT OF CAPILLARY RELATED INTERSTITIAL FLUID USING ULTRASOUND METHODS AND DEVICES

TITLE (FRENCH): MESURE DU FLUIDE INTERSTITIEL PROPRE AUX CAPILLAIRES UTILISANT DES METHODES ET DES DISPOSITIFS ECHOGRAPHIQUES
INVENTOR(S): LANG, Philipp;
MENDLEIN, John, D.
PATENT ASSIGNEE(S): LANG, Philipp;
MENDLEIN, John, D.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9908596	A1	19990225

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-US17238 A 19980819
PRIORITY INFO.: US 1997-08/914,527 19970819

L25 ANSWER 5 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998051282 PCTFULL ED 20020514
TITLE (ENGLISH): SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME
TITLE (FRENCH): MATRICES POREUSES SOLIDES, LEUR PROCEDE DE FABRICATION ET LEUR UTILISATION
INVENTOR(S): UNGER, Evan, C.
PATENT ASSIGNEE(S): IMARX PHARMACEUTICAL CORP.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9851282	A1	19981119

DESIGNATED STATES
W: AU BR CA CN JP KR NZ AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1998-US9570 A 19980512
PRIORITY INFO.: US 1997-60/046,379 19970513
US 1998-9/075,477 19980511

L25 ANSWER 6 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998036784 PCTFULL ED 20020514
TITLE (ENGLISH): COATED IMPLANTABLE MEDICAL DEVICE
TITLE (FRENCH): DISPOSITIF MEDICAL IMPLANTABLE DOTE D'UN REVETEMENT
INVENTOR(S): RAGHEB, Anthony, O.;
BATES, Brian, L.;
FEARNOT, Neal, E.;
KOZMA, Thomas, G.;
VOORHEES, William, D., III;
GERSHLICK, Anthony, H.
PATENT ASSIGNEE(S): COOK INCORPORATED
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9836784	A1	19980827

DESIGNATED STATES

```
       W:              AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
                       ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
                       LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
                       SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
                       KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
                       CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
                       CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.:     WO 1998-US3438       A  19980220
PRIORITY INFO.:        US 1997-60/038,459      19970220


=> d kwic 2

L25    ANSWER 2 OF 12    PCTFULL   COPYRIGHT 2006 Univentio on STN

CLMEN.  .  .  a drug and the drug is selected from
       the group consisting of- isotretinoin; oxazepain; lorazepam; piroxicam;
       loperamide;
       bromopheniramine; phenylpropanolanime; loratadine; famotidine;
       ordansetron; enalapril; captopril;
       phloroglucinol; nicergoline; acetaminophen; metapimazine;
       dihydroergotamine; fexofenadine-HCI
       and albuterol.
 .  .  .
       The method of claim 24, wherein the subject is selected from the group
       consisting
       of a geriatric subject, a subject with cancer, a subject who
       is post-surgically recovering, a child and
       a pregnant mother.


=> d ibib 7-12

L25    ANSWER 7 OF 12    PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:      1998032718 PCTFULL  ED 20020514
TITLE (ENGLISH):       NEW FATTY ACID DERIVATIVES
TITLE (FRENCH):        NOUVEAUX DERIVES D'ACIDE GRAS
INVENTOR(S):           MYHREN, Finn;
                       BORRETZEN, Bernt;
                       DALEN, Are;
                       SANDVOLD, Marit, Liland
PATENT ASSIGNEE(S):    NORSK HYDRO ASA;
                       MYHREN, Finn;
                       BORRETZEN, Bernt;
                       DALEN, Are;
                       SANDVOLD, Marit, Liland
LANGUAGE OF PUBL.:     English
DOCUMENT TYPE:         Patent
PATENT INFORMATION:
                       NUMBER              KIND     DATE
                       ---------------------------------
                       WO 9832718            A1 19980730
DESIGNATED STATES
       W:              AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
                       ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
                       LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
                       SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
                       GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
                       BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
                       CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.:     WO 1998-NO21          A  19980123
PRIORITY INFO.:        GB 1997-9701441.9        19970124
```

L25 ANSWER 8 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998032022 PCTFULL ED 20020514
TITLE (ENGLISH): GROWTH FACTOR-DEPENDENT DISEASES
TITLE (FRENCH): MALADIES LIEES AU FACTEUR DE CROISSANCE
INVENTOR(S): EPSTEIN, Richard, John
PATENT ASSIGNEE(S): IMPERIAL EXPLOITATION LIMITED;
EPSTEIN, Richard, John
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9832022	A1	19980723

DESIGNATED STATES
W: JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1998-GB33 A 19980115
PRIORITY INFO.: GB 1997-9700933.6 19970117

L25 ANSWER 9 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998018610 PCTFULL ED 20020514
TITLE (ENGLISH): EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES
TITLE (FRENCH): INCLUSION ET ENCAPSULATION DE PARTICULES A LIBERATION CONTROLEE
INVENTOR(S): VAN LENGERICH, Bernhard, H.
PATENT ASSIGNEE(S): VAN LENGERICH, Bernhard, H.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9818610	A1	19980507

DESIGNATED STATES
W: AU CA JP NO PL US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1997-US18984 A 19971027
PRIORITY INFO.: US 1996-60/029,038 19961028
US 1997-60/052,717 19970716

L25 ANSWER 10 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998017331 PCTFULL ED 20020514
TITLE (ENGLISH): SILVER IMPLANTABLE MEDICAL DEVICE
TITLE (FRENCH): DISPOSITIF MEDICAL IMPLANTABLE ET CONTENANT DE L'ARGENT
INVENTOR(S): BATES, Brian, L.;
OSBORNE, Thomas, A.;
ROBERTS, Joseph, W.;
FEARNOT, Neal, E.;
KOZMA, Thomas, G.;
RAGHEB, Anthony, O.;
VOORHEES, William, D., III
PATENT ASSIGNEE(S): COOK INCORPORATED;
MED INSTITUTE, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9817331	A1	19980430

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG

```
                        SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW SD
                        SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES
                        FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
                        GN ML MR NE SN TD TG
APPLICATION INFO.:      WO 1997-US19188      A  19971023
PRIORITY INFO.:         US 1996-60/029,158      19961024
                        US 1996-8/741,565       19961031
                        US 1997-8/803,843       19970224

L25    ANSWER 11 OF 12  PCTFULL  COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:       1997031654 PCTFULL  ED 20020514
TITLE (ENGLISH):        NITRIC OXIDE DONORS CAPABLE OF REDUCING TOXICITY FROM
                        DRUGS
TITLE (FRENCH):         DONNEURS D'OXYDE NITRIQUE CAPABLES DE DIMINUER LA
                        TOXICITE DE MEDICAMENTS
INVENTOR(S):            DEL SOLDATO, Piero
PATENT ASSIGNEE(S):     NICOX S.A.;
                        DEL SOLDATO, Piero
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:          Patent
PATENT INFORMATION:
                        NUMBER              KIND     DATE
                        ---------------------------------
                        WO 9731654           A1 19970904
DESIGNATED STATES
       W:               AL AU BB BG BR CA CN CZ EE GE HU IL IS JP KP KR LK LR
                        LT LV MG MK MN MX NO NZ PL RO RU SG SI SK TR TT UA US
                        UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT
                        BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
                        CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.:      WO 1997-EP873        A  19970224
PRIORITY INFO.:         IT 1996-MI96A000352     19960226

L25    ANSWER 12 OF 12  PCTFULL  COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:       1990006775 PCTFULL  ED 20020513
TITLE (ENGLISH):        A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR
                        SUSTAINED RELEASE OF DRUGS
TITLE (FRENCH):         NOUVELLE COMPOSITION DE LIPOSOMES NON PHOSPHOLIPIDIQUE
                        A LIBERATION SOUTENUE DE MEDICAMENTS
INVENTOR(S):            RADHAKRISHNAN, Ramachandran
PATENT ASSIGNEE(S):     LIPOSOME TECHNOLOGY, INC.
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:          Patent
PATENT INFORMATION:
                        NUMBER              KIND     DATE
                        ---------------------------------
                        WO 9006775           A1 19900628
DESIGNATED STATES
       W:               AT AU BE CH DE DK ES FI FR GB IT JP LU NL NO SE
APPLICATION INFO.:      WO 1989-US5525       A  19891206
PRIORITY INFO.:         US 1988-284,158         19881214
                        US 1988-284,216         19881214
                        US 1989-Not furnished   19891201


=> d kwic 12

L25    ANSWER 12 OF 12   PCTFULL   COPYRIGHT 2006 Univentio on STN

CLMEN.  .  .  enviroxime,
       ribavarin, rimantadine, amantadine, penicillin,
       erythromycin, tetracyclin, cephalothin, cefotaxime,
       carbenicillin, vancomycin, gentamycin, tobramycin,
```

piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin,
amikacin, amphotericin B. micozanole, apresoline, atenolol,
captopril, verapamil, **enalapril**, dopamine,
dextroamphetamine, pentamidine, pyribenzamine,
chlorpheniramine, diphenhydramine, interferon, interleukin-
. . .
enviroxime,
ribavarin, rimantadine, amantadine, penicillin,
erythromycin, tetracyclin, cephalothin, cefotaxime,
carbenicillin, vancomycin, gentamycin, tobramycin,
piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin,
amikacin, amphotericin B, micozanole, apresoline, atenolol,
captopril, verapamil, **enalapril**, dopamine,
dextroamphetamine, pentamidine, pyribenzamine,
chlorpheniramine, diphenhydramine, interferon, interleukin-
. . .
enviroxime,
ribavarin, rimantadine, amantadine, penicillin,
erythromycin, tetracyclin, cephalothin, cefotaxime,
carbenicillin, vancomycin, gentamycin, tobramycin,
piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin,
amikacin, amphotericin B, micozanole, apresoline, atenolol,
captopril, verapamil, **enalapril**, dopamine,
dextroamphetamine, pentamidine, pyribenzamine,
chlorpheniramine, diphenhydramine, interferon, interleukin-
. . .
enviroxime,
ribavarin, rimantadine, amantadine, penicillin,
erythromycin,F tetracyclin, cephalothin, cefotaxime,
carbenicillin, vancomycint gentamycin, tobramycin,
piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin,
amikacin, amphotericin B, micozanole, apresoline, atenolol,
captopril, verapamil, **enalapril**, dopaminer
dextroamphetaxine, pentamidine, pyribenzamine,
chlorpheniramine, diphenhydramine, interferon, interieukin-
. . .
enviroxime,
ribavarin, rimantadine, amantadine, penicillin,
erythromycinr tetracyclin, cephalothin, cefotaxime,
carbenicillin, vancomycin, gentamycin, tobramycin,
piperacillinr moxalactamr cefazolin, cefadroxil, cefoxitin,
amikacin, amphotericin B, micozanole,, apresoline,, atenolol,,
captopril, verapamil, **enalapril**, dopamine,
dextroamphetamine, pentamidine, pyribenzamine,
chlorpheniramine, diphenhydramine, interferon, interleukin-
. . .
cholesterol sulfate, 40
mole % of cholesterol and 10 mole t of the drug of Claim 25.
28a A method of suppressing **neoplastic** growth by
administering to a person in need of such treatment a
therapeutically effective amount of nonconventional liposome
composition comprising nonphospholipid lipids and. . .
. . .
enviroxime,
ribavarin, rimantadine, amantadine, penicillin,
erythromycin, tetracyclin, cephalothin, cefotaxime,
carbenicillin, vancomycin, gentamycin, tobramycin,
piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin,
amikacin, amphotericin B, micozanole, apresoline, atenolol,
captopril, verapamil, **enalapril**, dopamine,
dextroamphetamine, pentamidine, pyribenzamine,
chlorpheniramine, diphenhydramine, interferon, interleukin-
. . .

enviroxime,
ribavarin, rimantadine, amantadine, penicillin,
erythromycin, tetracyclin, cephalothin, cefotaxime,
carbenicillin, vancomycin, gentamycin, tobramycin,
piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin,
amikacin, amphotericin B, micozanole, apresoline, atenolol,
captopril, verapamil, **enalapril**, dopamine,
dextroamphetamine, pentamidine, pyribenzamine,
chlorpheniramine, diphenhydramine, interferon, interleukin-

```
=> d his

     (FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

     FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006
                E "LOSARTAN"/CN 25
L1            1 S E3
                E "ENALAPRIL"/CN 25
L2            1 S E3

     FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006
L3         4684 S L1 OR L2
L4       704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5          146 S L4 AND L3
L6           22 S L3 (L) L4
L7            3 S L6 NOT PY>2000
L8       266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9          220 S L8 AND L3
L10          46 S L8 (L) L3
L11          18 S L10 NOT PY>2000
L12           7 S L10 AND L4
L13        7727 S LOSARTAN OR ENALAPRIL
L14          92 S L13 (L) L4
L15          28 S L14 NOT PY>2000
L16          23 S L14 NOT PY>1999
L17           4 S L16 AND L8

     FILE 'PCTFULL' ENTERED AT 10:25:28 ON 26 APR 2006
L18        2831 S LOSARTAN OR ENALAPRIL
L19       96710 S CANCER? OR TUMOR? OR NEOPLAS?
L20        1575 S L18 AND L19
L21         571 S L18/CLM
L22       31673 S L19/CLM
L23         141 S L21 AND L22
L24          15 S L23 NOT PY>2000
L25          12 S L24 NOT PY>1999

=> s l24 not l25
L26           3 L24 NOT L25

=> d ibib 1-3

L26    ANSWER 1 OF 3     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2000074742 PCTFULL  ED 20020515
TITLE (ENGLISH):         DEVICES AND COMPOUNDS FOR TREATING ARTERIAL RESTENOSIS
TITLE (FRENCH):          DISPOSITIFS ET COMPOSES SERVANT A TRAITER LA RESTENOSE
                         ARTERIELLE
INVENTOR(S):             ZAHRADKA, PeterRP : ADE & COMPANY
PATENT ASSIGNEE(S):      CARDIO VASCULAR SOLUTIONS INC.;
                         ZAHRADKA, Peter
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
```

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000074742	A1	20001214

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL
SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE
DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-CA653 A 20000601
PRIORITY INFO.: US 1999-60/150,696 19990602

L26 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2000040227 PCTFULL ED 20020515
TITLE (ENGLISH): METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THE ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX
TITLE (FRENCH): PROCEDES DE TRAITEMENT D'ETATS ASSOCIES A L'ACCUMULATION D'UN EXCEDENT DE MATRICE EXTRACELLULAIRE
INVENTOR(S): NOBLE, Nancy, A.;
BORDER, Wayne, A.;
LAWRENCE, Daniel, A.
PATENT ASSIGNEE(S): UNIVERSITY OF UTAH;
AMERICAN NATIONAL RED CROSS;
NOBLE, Nancy, A.;
BORDER, Wayne, A.;
LAWRENCE, Daniel, A.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000040227	A2	20000713

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US179 A 20000105
PRIORITY INFO.: US 1999-60/114,795 19990105

L26 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2000001706 PCTFULL ED 20020515
TITLE (ENGLISH): N-TERMINAL SITE SELECTIVE INHIBITORS OF HUMAN ANGIOTENSIN CONVERSION ENZYME (ACE)
TITLE (FRENCH): INHIBITEURS SELECTIFS DE SITE N-TERMINAL DE L'ECA
INVENTOR(S): DIVE, Vincent;
COTTON, Joel;
CUNIASSE, Philippe;
YIOTAKIS, Athanasios;
CORVOL, Pierre;
MICHAUD, Annie;
CHAUVET, Marie-Therese;
MENARD, Joel;
EZAN, Eric
PATENT ASSIGNEE(S): COMMISSARIAT A L'ENERGIE ATOMIQUE;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE

MEDICALE INSERM;
DIVE, Vincent;
COTTON, Joel;
CUNIASSE, Philippe;
YIOTAKIS, Athanasios;
CORVOL, Pierre;
MICHAUD, Annie;
CHAUVET, Marie-Therese;
MENARD, Joel;
EZAN, Eric

LANGUAGE OF PUBL.: French
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000001706	A1	20000113

DESIGNATED STATES
W: CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1999-FR1581 A 19990701
PRIORITY INFO.: FR 1998-98/08464 19980702

=> d kwic 3

L26 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

CLMFR 10 Composition selon la revendication 8,
dans laquelle le traitement est un traitement anti-
cancereux.
. . .
la revendication 11,
dans laquelle le medicament est destine a reguler la
proliferation des cellules souches hematopoietiques de
patients soumis a un traitement anti-**cancereux**.
CH3
1 rooo)
CAPTOPRIL HS-CH2-CH - C- N - CH- COOH
il
0
COOH CH3
1 1 fooe)
ENALAPRIL CH2- CH2 c N - CH-COOH
0
0
il
FOSINOPRIL]]](CH2)4 - p - CH2C CH- COOH
Uri
FI Ga 1
% D'INHIBITION DU MUTANT N-TERMINAL ACTIF. . .

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006
E "LOSARTAN"/CN 25
L1 1 S E3
E "ENALAPRIL"/CN 25
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

```
L3          4684 S L1 OR L2
L4        704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5           146 S L4 AND L3
L6            22 S L3 (L) L4
L7             3 S L6 NOT PY>2000
L8        266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9           220 S L8 AND L3
L10           46 S L8 (L) L3
L11           18 S L10 NOT PY>2000
L12            7 S L10 AND L4
L13         7727 S LOSARTAN OR ENALAPRIL
L14           92 S L13 (L) L4
L15           28 S L14 NOT PY>2000
L16           23 S L14 NOT PY>1999
L17            4 S L16 AND L8

     FILE 'PCTFULL' ENTERED AT 10:25:28 ON 26 APR 2006
L18         2831 S LOSARTAN OR ENALAPRIL
L19        96710 S CANCER? OR TUMOR? OR NEOPLAS?
L20         1575 S L18 AND L19
L21          571 S L18/CLM
L22        31673 S L19/CLM
L23          141 S L21 AND L22
L24           15 S L23 NOT PY>2000
L25           12 S L24 NOT PY>1999
L26            3 S L24 NOT L25

=> s angiotensin II
           7881 ANGIOTENSIN
            128 ANGIOTENSINS
           7949 ANGIOTENSIN
                (ANGIOTENSIN OR ANGIOTENSINS)
         348075 II
           6036 IIS
         349694 II
                (II OR IIS)
L27         2257 ANGIOTENSIN II
                (ANGIOTENSIN(W)II)

=> s l27/ab
            497 ANGIOTENSIN/AB
              1 ANGIOTENSINS/AB
            497 ANGIOTENSIN/AB
                ((ANGIOTENSIN OR ANGIOTENSINS)/AB)
          22147 II/AB
             18 IIS/AB
          22161 II/AB
                ((II OR IIS)/AB)
L28          295 (ANGIOTENSIN II/AB)
                ((ANGIOTENSIN(W)II)/AB)

=> s l28 and l19
L29           43 L28 AND L19

=> s l18 and l29
L30           26 L18 AND L29

=> s l30 not py>2000
         592560 PY>2000
L31            8 L30 NOT PY>2000

=> s l30 not py>1999
         672418 PY>1999
```

L32 6 L30 NOT PY>1999

=> d ibib 1-6

L32 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998046266 PCTFULL ED 20020514
TITLE (ENGLISH): COMPOSITIONS CONTAINING AN ANGIOTENSIN II ANTAGONIST AND AN ANGIOTENSIN II AGONIST FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION
TITLE (FRENCH): COMPOSITIONS CONTENANT UN ANTAGONISTE DE L'ANGIOTENSINE II ET UN AGONISTE DE L'ANGIOTENSINE II, DESTINEES AU TRAITEMENT DES DYSERECTIONS
INVENTOR(S): KIFOR, Imre;
WILLIAMS, Gordon
PATENT ASSIGNEE(S): BRIGHAM & WOMEN'S HOSPITAL, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9846266	A1	19981022

DESIGNATED STATES
W: CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1998-US5893 A 19980326
PRIORITY INFO.: US 1997-60/041,875 19970411

L32 ANSWER 2 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998046224 PCTFULL ED 20020514
TITLE (ENGLISH): COMPOSITIONS AND METHOD FOR TREATING BLADDER DYSFUNCTION
TITLE (FRENCH): COMPOSITIONS ET PROCEDES POUR TRAITER LE DYSFONCTIONNEMENT DE LA VESSIE
INVENTOR(S): KIFOR, Imre;
WILLIAMS, Gordon;
SULLIVAN, Maryrose, P.
PATENT ASSIGNEE(S): BRIGHAM & WOMEN'S HOSPITAL, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9846224	A1	19981022

DESIGNATED STATES
W: CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1998-US5886 A 19980326
PRIORITY INFO.: US 1997-60/041,874 19970411
US 1997-60/041,875 19970411

L32 ANSWER 3 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998018496 PCTFULL ED 20020514
TITLE (ENGLISH): CONTRAST AGENTS
TITLE (FRENCH): AGENTS DE CONTRASTE
INVENTOR(S): KLAVENESS, Jo;
NAEVESTAD, Anne;
CUTHBERTSON, Alan
PATENT ASSIGNEE(S): NYCOMED IMAGING AS;
COCKBAIN, Julian;
KLAVENESS, Jo;
NAEVESTAD, Anne;
CUTHBERTSON, Alan
LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9818496	A2	19980507

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1997-GB2956	A	19971028
PRIORITY INFO.:	GB 1996-9622368.0		19961028
	GB 1996-9622365.6		19961028
	GB 1996-9622364.9		19961028
	GB 1996-9622369.8		19961028
	GB 1996-9622366.4		19961028
	GB 1996-9622367.2		19961028
	GB 1997-9700699.3		19970115
	GB 1997-9702195.0		19970204
	GB 1997-9706063.6		19970324

L32 ANSWER 4 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1995029674 PCTFULL ED 20020514
TITLE (ENGLISH): A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN
TITLE (FRENCH): METHODE DE MODIFICATION DE L'ACTIVITE DU RECEPTEUR DE L'ANGIOTENSINE POUR LE TRAITEMENT DU SYNDROME PREMENSTRUEL ET DE LA DOULEUR
INVENTOR(S): DePADOVA, Anthony, S.
PATENT ASSIGNEE(S): DePADOVA, Anthony, S.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9529674	A1	19951109

DESIGNATED STATES
W: AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1995-US5312	A	19950428
PRIORITY INFO.:	US 1994-8/235,468		19940429

L32 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1995006410 PCTFULL ED 20020514
TITLE (ENGLISH): ANTAGONIST OF ANGIOTENSIN II RECEPTORS
TITLE (FRENCH): ANTAGONISTE DES RECEPTEURS DE L'ANGIOTENSINE II
INVENTOR(S): GRISWOLD, Don, Edgar;
WHARTON, John
PATENT ASSIGNEE(S): SMITHKLINE BEECHAM CORPORATION;
GRISWOLD, Don, Edgar;
WHARTON, John
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9506410	A1	19950309

DESIGNATED STATES
W: AU BB BG BR BY CA CN CZ FI HU JP KP KR KZ LK MG MN MW
NO NZ PL RO RU SD SI SK UA US VN AT BE CH DE DK ES FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG
APPLICATION INFO.: WO 1994-US10258 A 19940901
PRIORITY INFO.: US 1993-8/115,968 19930901

L32 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1992020661 PCTFULL ED 20020513
TITLE (ENGLISH): N, N-DIACYLPIPERAZINES
TITLE (FRENCH): N, N-DIACYLPIPERAZINES
INVENTOR(S): ASHTON, Wallace, T.;
GREENLEE, William, J.;
WU, Mu, Tsu;
DORN, Conrad, P.;
MacCOSS, Malcolm;
MILLS, Sander, G.
PATENT ASSIGNEE(S): MERCK & CO., INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9220661	A1	19921126

DESIGNATED STATES
W: AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE
APPLICATION INFO.: WO 1992-US4189 A 19920519
PRIORITY INFO.: US 1991-703,953 19910522
US 1992-885,416 19920519

=> d kwic 5

L32 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ABEN The present invention relates to the use of an **angiotensin II** receptor antagonist in the manufacture of a medicament for the treatment of chronic inflammatory disease states.

DETD . . . for angiotensin in the regulation of tissue injury, proliferation and differen-tiation. As such this would include treatment of disorders such as **tumor** growth, i.e. **neoplastic** transformation and growth/metasis, bone marrow maturation and differen-tiation, skin maturation and differentiation, and hepatocyte maturation and differentiation. Chronic inflammatory diseases would. . .
. . .
Vol. 183, pp 989-995 (1992), and is a member of the superfamily of G protein-coupled transmembrane receptors. AT1 antagonists such as **losartan** (Whitebread et al., supra) al., J. Med. Chem., Vol. 34, pp 1514-1517 (1991), sensitivity to reducing agents such as dithiothreitol (DTT)(Whitebread et. . .
. . .
published January 20, 1988. Preferred compounds included within this class of All receptor antagonists are (hydroxymethyl)-imidazole (also referred to as **Losartan** herein); or a pharmaceutically acceptable salt thereof
. . .
µM PD123319 (AT1 receptors remain unblocked) or with 10 µM
µM PD123319 (AT1 receptors remain unblocked) or with 10 µM

losartan (AT2 receptors remain unblocked). Guanine nucleotide sensitivity of AII binding was assessed by coincubating sections with 0.25 nM [1251]AII and 1. . .

Losartan was kindly provided by DuPont Merck, Wilmington, SmithKline Beecham, King of Prussia, PA, U.S.A., and PD123319 by Parke-Davis, Ann Arbor, MI,. . .

. . . .

with osteoarthritis
and those with rheumatoid arthritis, specific ([1251](Sarl, Ile8)AII binding to each structure was completely inhibited by the AT1 antagonist **losartan** (10 µM), but was not significantly inhibited by the specific AT2 antagonist PD123319 (10 µM) (table 6) . Specific binding to. . .

. . . .

163, pp 264- 291
(1989); Weinstock et al., J. Med. Chem., Vol. 34, 1514-1517 (1991). Binding studies performed in the presence of **losartan** or PD123319 provide no evidence for the presence of AT2 receptors in synovium from any of these disease groups. The data. . .

. . . .

enzyme
inhibitors are listed. No patient had received glucocorticosteroids within the month prior to surgery. Abbreviations; AZA; azathioprine, CC; chondrocalcinosis, ENA; **enalapril**, MTX; methotrexate, OA; osteoarthritis, RA; rheumatoid arthritis, SZ; sulphasalazine

. . . .

2.00) c 3.39 (2.19 to 5.25)
Al
Al d 12.6 (6.6 to 24.6) d 8.32 (4.17 to 16.2) d 15.1 (7.41 to 31.6)
Losartan e 37.2 (15.9 to 87.1) e 102.3 (33.1 to 316.2)e 75.9 (32.4 to 177.8
1-(4carboxyphenyl)-
methyl)-1 H-imidazol-
5-yl]-2(2-thienyl)-
PD 123319. . . 10,000
nHill val=
(Sarl, lle8) 1.0(0.8 to 1.3) 1.2(0.9 to 1.6) 1.6(1.2 to 2.0)
All
All 1.0(0.6 to 1.5) 0.9(0.5 to 1.2) 0.8(0.5 to 1.2)
Losartan 0.6(0.4 to 0.8) 0.9(0.5 to 1.2)
0.6(0.3 to 0.8)
1-(4carboxyphenyl)-
methyl)-1H-
(2-thienyl)methyl-
2-propenoic acid
PD 123319 - - -

Footnotes to Table 5:
a. . . c (Sarl, Ile8) All was significantly more potent than All (each p lt; 0.05), d All was significantly more potent than **losartan** in lining cells 2-propenoic acid in all structures (each p lt; 0.05). e no significant differences were observed in Ki. . .

Effect of the specific AT1 antagonist **Losartan** and AT2 antagonist PD 123319 on binding of [1251] (Sarl, Ile8) anqiotensin II bindin to human s novium

Total Nonspecific **Losartan**
PD123319
Blood Vessels O A 7.9 (6.0 to 10) 2.4 (2.2 to 2.6)
a 2.9 (2.4 to 3.5) b 7.1 (5.1. . . 2.6
R A 3.0 (2.3 to 4.0) 1.6 (1.5 to 1.7) a 1.5 (1.5 to 1.6)
b 2.9 (2.1 to 4.1
a **Losartan** (10 µM) significantly inhibits binding to
each
structure in synovium from patients with osteoarthritis (OA)
or rheumatoid arthritis (RA) (each. . .

=> d ibib kwic 5-6

L32 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1995006410 PCTFULL ED 20020514
TITLE (ENGLISH): ANTAGONIST OF ANGIOTENSIN II RECEPTORS
TITLE (FRENCH): ANTAGONISTE DES RECEPTEURS DE L'ANGIOTENSINE II
INVENTOR(S): GRISWOLD, Don, Edgar;
WHARTON, John
PATENT ASSIGNEE(S): SMITHKLINE BEECHAM CORPORATION;
GRISWOLD, Don, Edgar;
WHARTON, John
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9506410	A1	19950309

DESIGNATED STATES
W: AU BB BG BR BY CA CN CZ FI HU JP KP KR KZ LK MG MN MW
NO NZ PL RO RU SD SI SK UA US VN AT BE CH DE DK ES FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG
APPLICATION INFO.: WO 1994-US10258 A 19940901
PRIORITY INFO.: US 1993-8/115,968 19930901
ABEN The present invention relates to the use of an **angiotensin
II** receptor antagonist in the
manufacture of a medicament for the treatment of chronic inflammatory
disease states.

DETD . . . for
angiotensin in the regulation of tissue injury,
proliferation and differen-tiation. As such this would
include treatment of disorders such as **tumor** growth, i.e.
neoplastic transformation and growth/metasis, bone marrow
maturation and differen-tiation, skin maturation and
differentiation, and hepatocyte maturation and
differentiation. Chronic inflammatory diseases would. . .
. . .
Vol. 183, pp 989-995 (1992), and is a member of the
superfamily of G protein-coupled transmembrane receptors.
AT1 antagonists such as **losartan** (Whitebread et al., supra)
al., J. Med. Chem., Vol. 34, pp 1514-1517 (1991),
sensitivity to reducing agents such as dithiothreitol
(DTT)(Whitebread et. . .
. . .
published January 20, 1988. Preferred compounds
included within this class of All receptor antagonists are
(hydroxymethyl)-imidazole (also referred to as **Losartan**
herein); or a pharmaceutically acceptable salt thereof
. . .
µM PD123319 (AT1 receptors remain unblocked) or with 10 µM
µM PD123319 (AT1 receptors remain unblocked) or with 10 µM

losartan (AT2 receptors remain unblocked). Guanine nucleotide sensitivity of AII binding was assessed by coincubating sections with 0.25 nM [1251]AII and 1. . .

Losartan was kindly provided by DuPont Merck, Wilmington, SmithKline Beecham, King of Prussia, PA, U.S.A., and PD123319 by Parke-Davis, Ann Arbor, MI,. . .

. . .

with osteoarthritis
and those with rheumatoid arthritis, specific ([1251](Sarl, Ile8)AII binding to each structure was completely inhibited by the AT1 antagonist **losartan** (10 µM), but was not significantly inhibited by the specific AT2 antagonist PD123319 (10 µM) (table 6) . Specific binding to. . .

. . .

163, pp 264- 291
(1989); Weinstock et al., J. Med. Chem., Vol. 34, 1514-1517 (1991). Binding studies performed in the presence of **losartan** or PD123319 provide no evidence for the presence of AT2 receptors in synovium from any of these disease groups. The data. . .

. . .

enzyme
inhibitors are listed. No patient had received glucocorticosteroids within the month prior to surgery. Abbreviations; AZA; azathioprine, CC; chondrocalcinosis, ENA; **enalapril**, MTX; methotrexate, OA; osteoarthritis, RA; rheumatoid arthritis, SZ; sulphasalazine

. . .

2.00) c 3.39 (2.19 to 5.25)
Al
Al d 12.6 (6.6 to 24.6) d 8.32 (4.17 to 16.2) d 15.1 (7.41 to 31.6)
Losartan e 37.2 (15.9 to 87.1) e 102.3 (33.1 to 316.2)e 75.9 (32.4 to 177.8
1-(4carboxyphenyl)-
methyl)-1 H-imidazol-
5-yl]-2(2-thienyl)-
PD 123319. . . 10,000
nHill val=
(Sarl, lle8) 1.0(0.8 to 1.3) 1.2(0.9 to 1.6) 1.6(1.2 to 2.0)
All
All 1.0(0.6 to 1.5) 0.9(0.5 to 1.2) 0.8(0.5 to 1.2)
Losartan 0.6(0.4 to 0.8) 0.9(0.5 to 1.2)
0.6(0.3 to 0.8)
1-(4carboxyphenyl)-
methyl)-1H-
(2-thienyl)methyl-
2-propenoic acid
PD 123319 - - -

Footnotes to Table 5:
a. . . c (Sarl, Ile8) All was significantly more potent than All (each p lt; 0.05), d All was significantly more potent than **losartan** in lining cells 2-propenoic acid in all structures (each p lt; 0.05). e no significant differences were observed in Ki. . .

Effect of the specific AT1 antagonist **Losartan** and AT2 antagonist PD 123319 on binding of [1251] (Sarl, Ile8) anqiotensin II bindin to human s novium

Total Nonspecific **Losartan**
PD123319
Blood Vessels O A 7.9 (6.0 to 10) 2.4 (2.2 to 2.6)
a 2.9 (2.4 to 3.5) b 7.1 (5.1. . . 2.6
R A 3.0 (2.3 to 4.0) 1.6 (1.5 to 1.7) a 1.5 (1.5 to 1.6)
b 2.9 (2.1 to 4.1
a **Losartan** (10 µM) significantly inhibits binding to
each
structure in synovium from patients with osteoarthritis (OA)
or rheumatoid arthritis (RA) (each. . .

L32 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1992020661 PCTFULL ED 20020513
TITLE (ENGLISH): N, N-DIACYLPIPERAZINES
TITLE (FRENCH): N, N-DIACYLPIPERAZINES
INVENTOR(S): ASHTON, Wallace, T.;
GREENLEE, William, J.;
WU, Mu, Tsu;
DORN, Conrad, P.;
MacCOSS, Malcolm;
MILLS, Sander, G.
PATENT ASSIGNEE(S): MERCK & CO., INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9220661	A1	19921126

DESIGNATED STATES
W: AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE
APPLICATION INFO.: WO 1992-US4189 A 19920519
PRIORITY INFO.: US 1991-703,953 19910522
US 1992-885,416 19920519

ABEN Diacylpiperazines of general structure (I) are: **angiotensin**
II (A-II) antagonists selective for
the type 2 (AT2) subtype useful in the treatment of cerebrovascular,
cognitive, and CNS disorders;
tachykinin. . .

DETD . . . processes leading to ovulation has
been reviewed (Andrade-Gordon, et al. Biochem,
Pharmacol., 42, 715-719 (1991)),
1 5
In addition, AT2 receptors are found in
neuronal **tumor** cells (Speth, et al, Peptide Res,, 2,
232-239 (1989)) and in transformed human neural cells
(Tallant, et al, Llypertension, 17, 1135-1143 (1991)).
. . .
of angiotensin II to
AT2 receptors in reproductive organs. The compounds
of the present invention are also useful as
anticancer agents for brain **cancers** and other **cancers**
wherein the AT2 receptor is prevelant,
SUBSTANCE P ANTAGONISM ASSAY
The compounds of this invention are useful
for antagonizing substance P in the treatment. . .
. . .
to
the hypertensive eye in solution in a suitable
ophthalmic vehicle, Also, these compounds may be
useful in the reversal of multidrug resistance in
tumor cells by enhancing the efficacy -of
chemotherapeutic agents. In add ition, these

compounds may have activity in blocking calcium channnels in insect brain. . .

. . .

These include acetylcholinesterase inhibitors such as heptylphysostigmine and tetrahydroacridine (THA; tacrine), muscarinic agonists such as oxotremorine, inhibitors of angiotensin-converting enzyme such as octylramipril, captopril, ceranapril, **enalapril**, lisinopril, fosinopril and zofenopril, centrally-acting calcium channel blockers and as nimodipine, and nootropic agents such as piracetam.

CLMEN 22 A method for inhibiting the growth of neruonal **tumor** cells which contain AT2 receptors in a patient in need thereof which comprises the administration to the patient of an effective amount of. . .

35 A method for the treatment of multidrug resistant **tumor** cells comprising the administration to a mammal in need of such treatment of an effective amount of the compound of Claim 1,

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

```
                E "LOSARTAN"/CN 25
L1            1 S E3
                E "ENALAPRIL"/CN 25
L2            1 S E3
```

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

```
L3         4684 S L1 OR L2
L4       704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5          146 S L4 AND L3
L6           22 S L3 (L) L4
L7            3 S L6 NOT PY>2000
L8       266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9          220 S L8 AND L3
L10          46 S L8 (L) L3
L11          18 S L10 NOT PY>2000
L12           7 S L10 AND L4
L13        7727 S LOSARTAN OR ENALAPRIL
L14          92 S L13 (L) L4
L15          28 S L14 NOT PY>2000
L16          23 S L14 NOT PY>1999
L17           4 S L16 AND L8
```

FILE 'PCTFULL' ENTERED AT 10:25:28 ON 26 APR 2006

```
L18        2831 S LOSARTAN OR ENALAPRIL
L19       96710 S CANCER? OR TUMOR? OR NEOPLAS?
L20        1575 S L18 AND L19
L21         571 S L18/CLM
L22       31673 S L19/CLM
L23         141 S L21 AND L22
L24          15 S L23 NOT PY>2000
L25          12 S L24 NOT PY>1999
L26           3 S L24 NOT L25
L27        2257 S ANGIOTENSIN II
L28         295 S L27/AB
```

```
L29          43 S L28 AND L19
L30          26 S L18 AND L29
L31           8 S L30 NOT PY>2000
L32           6 S L30 NOT PY>1999
```